WeVote

Bill

Bill

SB 987

Corporate Income Tax - Addition Modification - Direct-to-Consumer Pharmaceutical Advertising

2026 Regular Session Introduced by Karen Young

SB 987 modifies Maryland corporate income tax treatment for direct-to-consumer pharmaceutical advertising expenses, affecting tax deductions for drug marketing costs.

Hearing 3/11 at 1:00 p.m.
0
WeVote Research Nonpartisan
Bill Summary · SB 987

Legislative bill overview

SB 987 would modify Maryland's corporate income tax code regarding direct-to-consumer (DTC) pharmaceutical advertising. The bill appears to create a tax modification or adjustment related to how corporations can deduct or account for DTC pharmaceutical advertising expenses. The specific mechanism requires the full bill text to analyze precisely, but the title suggests it addresses the tax treatment of marketing costs for drugs advertised directly to consumers.

Why is this important

Pharmaceutical advertising is a significant business expense, and how it's taxed affects both corporate profitability and state revenue. DTC advertising represents billions in annual spending nationwide and influences both consumer behavior and healthcare costs. Changes to tax treatment could shift incentives for pharmaceutical marketing strategies or generate/reduce state tax revenue depending on the modification's direction.

Potential points of contention

  • State revenue impact: Whether the modification increases or decreases corporate tax liability will affect Maryland's budget and potentially trigger fiscal impact debates
  • Healthcare cost implications: Limiting DTC advertising tax deductions could reduce marketing spending, while expanding deductions could encourage more advertising that influences prescription patterns
  • Fairness and competition: The modification may advantage certain pharmaceutical companies or marketing approaches over others, raising questions about economic equity

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.